The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data
Yıl: 2020 Cilt: 7 Sayı: 2 Sayfa Aralığı: 167 - 173 Metin Dili: İngilizce DOI: 10.14744/nci.2019.22697 İndeks Tarihi: 18-09-2020
The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data
Öz: OBJECTIVE: This study aims to evaluate the efficacy and safety of the addition of 10 or 25 mg of empagliflozin to patientswith type 2 diabetes mellitus using a maximum tolerable dose of metformin and gliclazide.METHODS: A total of 60 patients who had been receiving a maximum tolerable dose of metformin plus gliclazide. wasdivided into two groups in this study. In the first group (Group 1, n=32), 10 mg empagliflozin was added to the current treatment once a day, and in the second group (Group 2, n=28) 25 mg empagliflozin was added to the same treatment once a day.Biochemical results, weight and blood pressure changes of the patients in both groups were evaluated before and after 12weeks of empagliflozin addition. Patients who developed urinary tract and genital infections after treatment were recorded.RESULTS: There was a statistically significant decrease in HbA1c in both groups after empagliflozin treatment (Group 1,p<0.001 and Group2, p=0.001). When the lipid profile was evaluated, no significant difference was found between basaland post-treatment parameters (p>0.05). Patients in Group 1 and Group 2 lost 2.6±1.2 and 3.8±2.0 kg of body weight,respectively (p<0.0001 for each). There were also significant reductions in systolic and diastolic blood pressure for groups 1and 2 (p<0.0001 for each). Although there was a numerical increase in the urinary tract and genital infections in both groupsafter empagliflozin treatment, there was no statistically significant difference compared to the pre-treatment period (p>0.05).CONCLUSION: Two doses of empagliflozin added to the present treatments showed a dose-independent improvement inglycemic control and a neutral effect on lipid metabolism.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427– 43.
- 2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–96.
- 3. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012;14:424–32.
- 4. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 2015;12:78–89.
- 5. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, et al; EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396–404.
- 6. Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al; EMPA-REG EXTEND™ PIO investigators. Empagliflozin as Addon Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clin Ther 2015;37:1773–88.e1.
- 7. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124–36.
- 8. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9.
- 9. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83–90.
- 10. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:721–8.
- 11. Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, Kim G, et al. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clin Ther 2016;38:1299–313.
- 12. Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014;40:S28–34.
- 13. Lund SS, Sattar N, Salsali A, Crowe S, Broedl UC, Ginsberg HN. Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes. Diabetologie und Stoffwechsel 2016;11:135.
- 14. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes 2016;65:2032–8.
- 15. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154–60.
- 16. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208–19.
- 17. Dai X, Luo ZC, Zhai L, Zhao WP, Huang F. Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Ther 2018;9:753–70.
| APA | Özçelik S, Celik M, VURAL A, Aydın B (2020). The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. , 167 - 173. 10.14744/nci.2019.22697 |
| Chicago | Özçelik Serhat,Celik Mehmet,VURAL AŞKI,Aydın Bünyamin The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. (2020): 167 - 173. 10.14744/nci.2019.22697 |
| MLA | Özçelik Serhat,Celik Mehmet,VURAL AŞKI,Aydın Bünyamin The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. , 2020, ss.167 - 173. 10.14744/nci.2019.22697 |
| AMA | Özçelik S,Celik M,VURAL A,Aydın B The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. . 2020; 167 - 173. 10.14744/nci.2019.22697 |
| Vancouver | Özçelik S,Celik M,VURAL A,Aydın B The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. . 2020; 167 - 173. 10.14744/nci.2019.22697 |
| IEEE | Özçelik S,Celik M,VURAL A,Aydın B "The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data." , ss.167 - 173, 2020. 10.14744/nci.2019.22697 |
| ISNAD | Özçelik, Serhat vd. "The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data". (2020), 167-173. https://doi.org/10.14744/nci.2019.22697 |
| APA | Özçelik S, Celik M, VURAL A, Aydın B (2020). The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. İstanbul Kuzey Klinikleri, 7(2), 167 - 173. 10.14744/nci.2019.22697 |
| Chicago | Özçelik Serhat,Celik Mehmet,VURAL AŞKI,Aydın Bünyamin The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. İstanbul Kuzey Klinikleri 7, no.2 (2020): 167 - 173. 10.14744/nci.2019.22697 |
| MLA | Özçelik Serhat,Celik Mehmet,VURAL AŞKI,Aydın Bünyamin The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. İstanbul Kuzey Klinikleri, vol.7, no.2, 2020, ss.167 - 173. 10.14744/nci.2019.22697 |
| AMA | Özçelik S,Celik M,VURAL A,Aydın B The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. İstanbul Kuzey Klinikleri. 2020; 7(2): 167 - 173. 10.14744/nci.2019.22697 |
| Vancouver | Özçelik S,Celik M,VURAL A,Aydın B The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. İstanbul Kuzey Klinikleri. 2020; 7(2): 167 - 173. 10.14744/nci.2019.22697 |
| IEEE | Özçelik S,Celik M,VURAL A,Aydın B "The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data." İstanbul Kuzey Klinikleri, 7, ss.167 - 173, 2020. 10.14744/nci.2019.22697 |
| ISNAD | Özçelik, Serhat vd. "The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data". İstanbul Kuzey Klinikleri 7/2 (2020), 167-173. https://doi.org/10.14744/nci.2019.22697 |
